A new molecule designed to treat Alzheimer's disease has significant promise and is potentially the safest to date. The molecule is a highly potent beta-secretase inhibitor with unique features that ensure it goes only to its target and does not affect healthy physiological processes.
Scientists have identified a key molecular player in a chain of events in the body that can lead to fatty liver disease, Type 2 diabetes and other metabolic abnormalities associated with obesity. By blocking this molecule, the researchers were able to reverse some of the pathology it caused in obese mice.
Chemicals similar to those found in cannabis form the basis of a new drug that is being trialed in cancer patients. The trial will investigate its potential for treating patients with a variety of solid tumors. The drug, called dexanabinol, is from a family of compounds called cannabinoids.
Scientists have shown how to synthesize in the laboratory an important set of natural compounds known as terpenes. The largest class of chemicals made by living organisms, terpenes are made within cells by some of the most complex chemical reactions found in biology.
Wheaton has introduce the R2P 2.0 is the first touch screen, Ethernet network-capable roller culture device for the vaccine and biologics industry.
ViroStat has released a new set of monoclonal antibodies to the HRP II protein of P. falciparum. These antibodies should be useful to researchers and those needing to develop rapid tests for this protein.
Theravance Inc. and Alfa Wassermann S.p.A. announced that they have entered into an exclusive development and commercialization agreement in certain countries for velusetrag, Theravance's investigational 5-HT4 agonist in development for gastrointestinal motility disorders.
Novo Nordisk is investing $100 million to expand its science facilities in Beijing. The 12,000m2 center will make it possible to increase the number of science employees from the current 130 to 200, with extra space available to accommodate additional future growth.
A new report predicts that the 2014 introduction of biosimilars to the United States, as well as the realization of massive potential in the emerging markets of Asia, mean that biosimilars are set to take a sizable chunk of the global biopharmaceuticals market by 2020.
Researchers have published the first highly detailed description of how neurotensin, a neuropeptide hormone which modulates nerve cell activity in the brain, interacts with its receptor. Their results suggest that neuropeptide hormones use a novel binding mechanism to activate G-protein coupled receptors.
Pfizer Inc. announced top-line results from a Phase 3 open-label long-term safety study of investigational agent ALO-02 (oxycodone hydrochloride and naltrexone hydrochloride extended-release capsules) in patients with moderate-to-severe chronic, non-cancer pain.
The Centre for Bio Separations Technology and BIA Separations have signed an agreement to work together and develop bioseparation platforms and technologies, as well as providing technical support, contract research, and services to the biopharmaceutical industry.
Mayne Pharma Group Ltd. has entered into a binding agreement to acquire Greenville, North Carolina-based Metrics Inc., a privately-owned provider of contract development services to the pharmaceutical industry that also develops and manufactures niche generic drugs.
Merck announced Phase 2b data for MK-3102, a once-weekly DPP-4 inhibitor for the treatment of type 2 diabetes. MK-3102 significantly lowered blood sugar in a 12-week study compared with placebo, with an incidence of symptomatic hypoglycemia that was similar to placebo.
According to the World Health Organization, depression affects more than 350 million people globally, and although there are known effective treatments, access to such treatments is problematic in some countries, with sometimes fewer than 10% of those in need receiving treatment.